Rates of CNS relapse are similar in DLBCL patients who receive high-dose IV methotrexate and those who receive IT methotrexate, phase 3 data suggest.
Combination treatment with teclistamab and talquetamab has demonstrated activity in patients with relapsed or refractory multiple myeloma.
Second-line treatment with axicabtagene ciloleucel can improve overall survival when compared to standard care in patients with relapsed or refractory large B-cell lymphoma.
A phase 3 trial suggests that ponatinib is more effective than imatinib for patients with newly diagnosed Ph+ acute lymphoblastic leukemia.
An all-oral triplet regimen is safe and effective in patients with newly diagnosed acute promyelocytic leukemia, a phase 2 trial suggests.
Epcoritamab elicits durable responses in patients with relapsed or refractory large B-cell lymphoma.
The CARMEN regimen appears effective in patients with MYC-rearranged aggressive lymphoma, including those who are HIV-positive.
Results from 4 trials presented at ASH 2022 may help inform the treatment of newly diagnosed and relapsed/refractory follicular lymphoma.
Early results appear promising for frontline asciminib in patients with chronic phase chronic myeloid leukemia, according to researchers.